On July 18, US crude oil September futures rose 0.9% and closed at $67.75 per barrel. In the last three trading sessions, US crude oil September futures have been struggling to close above the $68.00 mark.
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi.
The New York Rangers have carried the form that made them the NHL's best regular-season team straight into the postseason. The Rangers visit the Carolina Hurricanes in Saturday night's Game 4, with the Presidents' Trophy winner on the verge of sweeping past the team that finished third in the NHL standings.
DALLAS, May 10, 2024--Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE: SNDA), a leading owner-operator and investor in communities and services for seniors, today announced the appointment of Max Levy to the newly created role of Chief Investment Officer ("CIO"). In addition, the Company also announced today that Lilly H. Donohue will be appointed to the Board.
Austin, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend the date by which the Company must complete its initial business combination from May 14, 2024 to June 14, 2024, Acri Capital Sponsor LLC, the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of $50,000 (the “New Monthly Extension Payment”). Pursuant to th
PEORIA, Ill., May 10, 2024--RLI Corp. announces Deb Millum as new Vice President, Claim.
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron BoardDr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company’s Annual Meeting of StockholdersNeha Motwani, former managing director and senior healthcare investment banker at William Blair, Truist, and Oppenheimer and Company, also has been nominated as a candidate for the Boa
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employ
New York, NY, May 10, 2024 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (NASDAQ: BYNO (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $105,000, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from May 12, 2024 to June 12, 2024 (the “Extension”). The Extension is the
BOCA RATON, Fla., May 10, 2024--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.
DAVIDSON, N.C., May 10, 2024--Ingersoll Rand Inc. (NYSE: IR) (the "Company" or "Ingersoll Rand"), a global provider of mission-critical flow creation and industrial solutions, announced today that the Company has successfully completed a series of transactions issuing Senior Unsecured Bonds and putting in place a new Senior Unsecured Revolving Credit Facility.
Investors are listening out for a parade of Fed speakers to test a growing confidence that a rate cut is on the way.
Broadcom just ended the reign of Nvidia, usurping the top spot on this list of new buys by the best mutual funds.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript May 9, 2024 Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15985 EPS, expectations were $-0.06. Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning […]
Tesla Chief Executive Elon Musk on Friday said the EV giant is spending half a billion dollars to build out its supercharger stations this year, even as the Tesla head recently dismissed the company's entire supercharger team. Musk took to the social media platform X early Friday claiming that Tesla will spend more than $500 million to expand its supercharger network and "create thousands" of new chargers in 2024. In the first quarter, Tesla supercharger stations totaled 6,249, up 26% vs. Q1 2023.
Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.
Zay Jones was released by the Jaguars last month after two seasons.
Allegro MicroSystems, Inc. (NASDAQ:ALGM) Q4 2024 Earnings Call Transcript May 9, 2024 Allegro MicroSystems, Inc. misses on earnings expectations. Reported EPS is $-0.03658 EPS, expectations were $0.21. ALGM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome […]
Yellen spoke during a meeting of the Financial Stability Oversight Council, a regulatory body she chairs and which was created after the 2007-2009 financial crisis. The council, whose members head other top financial regulators, voted unanimously to approve publishing a report and related recommendations on the issue. Regulators are moving to cover what they say is a gap in their power to address risk in what is now a large and growing majority of the mortgage market.
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 mill
ALAMEDA, Calif., May 10, 2024--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.
Yahoo Finance